Skip to main content

Table 2 Characteristics of patients enrolled and not enrolled in the study

From: Obtaining informed consent for clinical tumor and germline exome sequencing of newly diagnosed childhood cancer patients

Characteristic Enrolled (n = 100) Declined (n = 21) P-value
Median age in years (range) 5.1 (0.1-17.0) 4.0 (0.1-14.2) 0.73
Female gender 45 (45%) 5 (24%) 0.09
Ethnicity    1a
  Hispanic 43 (43%) 10 (48%)  
  Non-Hispanic 51 (51%) 11 (52%)  
  Not reported 6 (6%) -  
Race    0.17b
  White 56 (56%) 18 (85%)  
  Black or African American 12 (12%) 1 (5%)  
  Asian 4 (4%) 1 (5%)  
  American Indian or Alaska Native 4 (4%) 1 (5%)  
  Multiple 6 (6%) -  
  Not reported 18 (18%) -  
Tumor location    0.22
  CNS 33 (33%) 10 (48%)  
  Non-CNS 67 (67%) 11 (52%)  
Tumor metastatic at diagnosis 34 (34%) ND  
Adjuvant tumor treatment planned 82 (82%) ND  
Tumor available for WES 84 (84%) 14 (67%) 0.12
Interpreter and Spanish consent form used 15 (15%) 4 (19%) 0.74
Median days from surgery to study decision (range) 36 (5-63) 42 (20-61) 0.052
  1. aP-value was calculated with ‘Not reported’ subjects excluded. bComparison was made between ‘White’ versus others with ‘Not reported’ subjects excluded. Two sample rank sum tests were used to compare the continuous data and Fisher’s exact tests were used for the categorical data. CNS, central nervous system; ND, not determined; WES, whole exome sequencing.